Relay Therapeutics, Inc. Capital Expenditures
Relay Therapeutics, Inc. (RLAY) reported Capital Expenditures of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- Relay Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $1.00K.
- Relay Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was -$1.00K, a 100.44% decline year-over-year.
- Relay Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-06-30 was $26.00K, a 136.36% increase year-over-year.
- Relay Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-03-31 was $384.00K, a 78.43% decline year-over-year.
- Relay Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $410.00K, a 79.68% decline from fiscal 2024.
- Relay Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $2.02M, a 51.09% decline from fiscal 2023.
- Relay Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $4.13M, a 54.47% decline from fiscal 2022.
- Relay Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $9.06M, a 161.08% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $26.00K derived: sum of 3 quarters · filed 2026-08-06 | $410.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $25.00K derived: sum of 2 quarters · filed 2026-08-06 | $409.00K 10-Q · filed 2025-11-06 | $409.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $410.00K 10-Q · filed 2026-08-06 | $410.00K derived: sum of 3 quarters · filed 2026-08-06 | $637.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $384.00K 10-Q · filed 2026-05-05 | $384.00K derived: sum of 2 quarters · filed 2026-05-05 | $611.00K derived: sum of 3 quarters · filed 2026-05-05 | $622.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $227.00K derived: sum of 2 quarters · filed 2026-02-26 | $238.00K derived: sum of 3 quarters · filed 2026-02-26 | $2.02M 10-K · filed 2026-02-26 |
| 2024-09-30 | $227.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $238.00K derived: sum of 2 quarters · filed 2025-11-06 | $2.02M 10-Q · filed 2025-11-06 | $2.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.79M 10-Q · filed 2025-08-07 | $1.91M derived: sum of 3 quarters · filed 2026-02-26 | $2.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.78M 10-Q · filed 2025-05-05 | $1.90M derived: sum of 2 quarters · filed 2026-02-26 | $2.49M derived: sum of 3 quarters · filed 2026-02-26 | $3.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $708.00K derived: sum of 2 quarters · filed 2026-02-26 | $2.21M derived: sum of 3 quarters · filed 2026-02-26 | $4.13M 10-K · filed 2026-02-26 |
| 2023-09-30 | $590.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.09M derived: sum of 2 quarters · filed 2024-11-06 | $4.01M 10-Q · filed 2024-11-06 | $6.32M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.42M 10-Q · filed 2024-08-06 | $5.73M derived: sum of 3 quarters · filed 2025-02-26 | $7.83M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $1.92M 10-Q · filed 2024-05-02 | $4.23M derived: sum of 2 quarters · filed 2025-02-26 | $6.33M derived: sum of 3 quarters · filed 2025-02-26 | $8.18M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $4.41M derived: sum of 2 quarters · filed 2025-02-26 | $6.27M derived: sum of 3 quarters · filed 2025-02-26 | $9.06M 10-K · filed 2025-02-26 |
| 2022-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $3.95M derived: sum of 2 quarters · filed 2023-11-02 | $6.75M 10-Q · filed 2023-11-02 | $7.63M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $4.65M 10-Q · filed 2023-08-08 | $5.53M derived: sum of 3 quarters · filed 2024-02-22 | $7.27M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $2.79M 10-Q · filed 2023-05-04 | $3.67M derived: sum of 2 quarters · filed 2024-02-22 | $5.41M derived: sum of 3 quarters · filed 2024-02-22 | $5.79M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $880.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.62M derived: sum of 2 quarters · filed 2024-02-22 | $3.00M derived: sum of 3 quarters · filed 2024-02-22 | $3.47M 10-K · filed 2024-02-22 |
| 2021-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.12M derived: sum of 2 quarters · filed 2022-11-03 | $2.59M 10-Q · filed 2022-11-03 | $2.65M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $379.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $855.00K 10-Q · filed 2022-08-04 | $919.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.35M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $476.00K 10-Q · filed 2022-05-05 | $540.00K derived: sum of 2 quarters · filed 2023-02-23 | $973.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.39M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $497.00K derived: sum of 2 quarters · filed 2023-02-23 | $911.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.93M 10-K · filed 2023-02-23 |
| 2020-09-30 | $433.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $847.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.87M 10-Q · filed 2021-11-10 | $2.46M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $414.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.43M 10-Q · filed 2021-08-12 | $2.03M derived: sum of 3 quarters · filed 2022-02-24 | $4.42M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $1.02M 10-Q · filed 2021-05-13 | $1.62M derived: sum of 2 quarters · filed 2022-02-24 | $4.00M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.98M derived: sum of 2 quarters · filed 2022-02-24 | $8.00M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $2.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $7.40M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $5.02M 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |